Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

bioTheranostics develops and provides innovative oncology tests to support targeted disease management.

bioT3 is a suite of genomic-based tests that provide diagnostic and therapeutic information for metastatic cancer patients at any stage across the continuum of care.

  • CancerTYPE ID® – Molecular classification for definitive diagnosis of tumor type and subtype
    Learn More >
  • CancerTARGET ID – (Formerly PRÉCIS®) Actionable tumor-specific biomarkers for the selection of on-label targeted therapies
    Learn More >
  • CancerTREATMENT ID – Next Generation Sequencing (NGS) + multi-platform biomarkers for comprehensive treatment options
    Learn More >

Breast Cancer IndexSM (BCI) provides full risk assessment, with the unique ability to predict both early and late recurrence, as well as benefit from extended endocrine therapy.
Learn More >